Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 24/10/2017

Debbie Rigby takes a look at the latest in research news Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations Onabotulinum toxin A (BoNT-A) is approved treatment for the prevention of chronic migraine. Its efficacy increases considerably over time during long-term treatments, significantly varying among patients. Short duration of migraine,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Funding secured for non-8CPA programs

Medschecks and Diabetes MedsCheck are included and funded under the 8CPA. The programs under the 8CPA will be undergoing a…

Anthony Tassone

Eli Lilly clarifies Mounjaro availability

One would think they could have made a commercial decision eith a needle maker to supply requisite number of needles…

Erin Threlfall

Funding secured for non-8CPA programs

This is a big step forward in securing the sustainability and viability of HMRs and RMMRs. Remember there is an…

Debbie Rigby

Funding secured for non-8CPA programs

So well done to the PSA for securing this funding. So important that these very valuable program finally gets looked…

Bente Hart

Research Roundup

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.